Stay updated with breaking news from Modupe Idowu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A medication that appeared to stabilize the function and shape of red blood cells in an earlier study for patients with sickle cell disease is now part of a Pha
Winners emerge in Rev. Idowu Foundation scholarship By Dipo Ogunsola THE trio of Emmanuel Edache Ejelewoicho, Babalola Oreoluwa Faith and Emmanuel
– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo –
Results of the phase 2 RISE UP trial offer additional perspective into the benefit-risk profile of mitapivat in patients with sickle cell disease.
– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support